CoChat

Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice

Open access

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine the role of glucagon action in the metabolic phenotype of untreated insulin deficiency. RESEARCH DESIGN AND METHODS: We compared pertinent clinical and metabolic parameters in glucagon receptor-null (Gcgr−/−) mice and wild-type (Gcgr+/+) controls after equivalent destruction of β-cells. We used a double dose of streptozotocin to maximize β-cell destruction. RESULTS: Gcgr+/+ mice became hyperglycemic (>500 mg/dL), hyperketonemic, polyuric, and cachectic and had to be killed after 6 weeks. Despite comparable β-cell destruction in Gcgr−/− mice, none of the foregoing clinical or laboratory manifestations of diabetes appeared. There was marked α-cell hyperplasia and hyperglucagonemia (∼1,200 pg/mL), but hepatic phosphorylated cAMP response element binding protein and phosphoenolpyruvate carboxykinase mRNA were profoundly reduced compared with Gcgr+/+ mice with diabetes—evidence that glucagon action had been effectively blocked. Fasting glucose levels and oral and intraperitoneal glucose tolerance tests were normal. Both fasting and nonfasting free fatty acid levels and nonfasting β-hydroxy butyrate levels were lower. CONCLUSIONS: We conclude that blocking glucagon action prevents the deadly metabolic and clinical derangements of type 1 diabetic mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-0426

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. A: Comparison of plasma glucagon levels in Gcgr+/+ (■) and Gcgr−/− (□) mice before and 6 weeks after STZ induction of β-cell destruction. B: Glucagon in Gcgr+/+ mice before and after STZ. C: Representative immunoblots for CREB and P-CREB in livers of Gcgr+/+ (■) and Gcgr−/− (□) mice after β-cell destruction by treatment with STZ and in untreated controls (upper panel). The P-CREB/CREB ratio in densitometric units in six Gcgr+/+ (■) and six Gcgr−/− (□) mice after β-cell destruction by treatment with STZ (lower panel).
FIG. 1. A: Comparison of plasma glucagon levels in Gcgr+/+ (■) and Gcgr−/− (□) mice before and 6 weeks after STZ induction of β-cell destruction. B: Glucagon in Gcgr+/+ mice before and after STZ. C: Representative immunoblots for CREB and P-CREB in livers of Gcgr+/+ (■) and Gcgr−/− (□) mice after β-cell destruction by treatment with STZ and in untreated controls (upper panel). The P-CREB/CREB ratio in densitometric units in six Gcgr+/+ (■) and six Gcgr−/− (□) mice after β-cell destruction by treatment with STZ (lower panel).CC BY-NC-ND · PubMed Central
FIG. 2. A: Comparison of food intake in nondiabetic and STZ-treated Gcgr+/+ (■) and Gcgr−/− (□) mice (n = 6). B: Comparison of body weight in Gcgr+/+ (■) and Gcgr−/− (□) before and after STZ induction of β-cell destruction. C: Comparisons of weekly nonfasting glucose levels in Gcgr+/+ (●) and Gcgr−/− (□) after STZ-induced β-cell destruction, and overnight fasting glucose levels for Gcgr+/+ (♦) and Gcgr−/− (◇) at the end of the study (n = 6). D: Glucose values for oral glucose tolerance test (OGTT) (2 g/kg) performed after a 16-h fast in normal Gcgr+/+ (●), Gcgr−/− (☐), and STZ-treated Gcgr−/− (▲) mice (n = 4). E: Insulin levels for OGTT in normal Gcgr+/+ (●), Gcgr−/− (☐), and STZ-treated Gcgr−/− (▲) mice (n = 4).
FIG. 2. A: Comparison of food intake in nondiabetic and STZ-treated Gcgr+/+ (■) and Gcgr−/− (□) mice (n = 6). B: Comparison of body weight in Gcgr+/+ (■) and Gcgr−/− (□) before and after STZ induction of β-cell destruction. C: Comparisons of weekly nonfasting glucose levels in Gcgr+/+ (●) and Gcgr−/− (□) after STZ-induced β-cell destruction, and overnight fasting glucose levels for Gcgr+/+ (♦) and Gcgr−/− (◇) at the end of the study (n = 6). D: Glucose values for oral glucose tolerance test (OGTT) (2 g/kg) performed after a 16-h fast in normal Gcgr+/+ (●), Gcgr−/− (☐), and STZ-treated Gcgr−/− (▲) mice (n = 4). E: Insulin levels for OGTT in normal Gcgr+/+ (●), Gcgr−/− (☐), and STZ-treated Gcgr−/− (▲) mice (n = 4).CC BY-NC-ND · PubMed Central
FIG. 3. Comparison of fasting (▨) and nonfasting FFAs () (A) and nonfasting β-OH butyrate levels (B) in STZ-treated Gcgr+/+ (■) and Gcgr−/− (□) mice and untreated controls (N = 6).
FIG. 3. Comparison of fasting (▨) and nonfasting FFAs () (A) and nonfasting β-OH butyrate levels (B) in STZ-treated Gcgr+/+ (■) and Gcgr−/− (□) mice and untreated controls (N = 6).CC BY-NC-ND · PubMed Central
FIG. 4. Comparison of the ratio of PEPCK mRNA to 36B4 mRNA (A) and plasma lactate levels (B) in STZ-treated Gcgr+/+ (■) and Gcgr−/− (□) mice (N = 6).
FIG. 4. Comparison of the ratio of PEPCK mRNA to 36B4 mRNA (A) and plasma lactate levels (B) in STZ-treated Gcgr+/+ (■) and Gcgr−/− (□) mice (N = 6).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

Metadata

Authors
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Albert Einstein College of Medicine (US)
  • VA North Texas Health Care System (US)
Corresponding author
Unger, Roger H.
Venue
Diabetes
Published
2011-01-21
Volume
60
Issue
2
Pages
391-397
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W1986861420
Cited by
327
References
47
Citations by year
2026: 4 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 26 · 2016: 32 · 2015: 40 · 2014: 25 · 2013: 23 · 2012: 26
FWCI
32.44
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R21DK081194, DK081194)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
glucagon receptor, type 1 diabetes, insulin deficiency, beta cell destruction, streptozotocin, alpha cell hyperplasia, hyperglucagonemia, phosphoenolpyruvate carboxykinase, ketogenesis, hyperketonemia, glucose tolerance, free fatty acids, beta-hydroxybutyrate
MeSH terms
Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Enzyme-Linked Immunosorbent Assay, Fatty Acids, Glucagon, Hyperglycemia, Immunohistochemistry, Insulin, Insulin-Like Growth Factor I, Liver, Pancreas, Radioimmunoassay, Blotting, Western, Receptors, Glucagon, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.